The Cholangiocarcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cholangiocarcinoma pipeline products will significantly revolutionize the Cholangiocarcinoma market dynamics.
Cholangiocarcinoma Overview
Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation. The major function of the bile duct is to move a fluid called bile from the liver and gallbladder to the small intestine, where it helps digest the fats in food. The causes of the abnormal proliferation in the bile ducts’ epithelial cells leading to tumors are unknown and most cases occur sporadically
Cholangiocarcinoma (CCAs) are classified into Intrahepatic and Extrahepatic. CCA which arise in the liver parenchyma beyond the second-order bile ducts, being categorized as intrahepatic form (ICCA), or arise in the bile ducts outside the liver parenchyma, considered an extrahepatic form (E-CCA).
Some of the key facts of the Cholangiocarcinoma Market Report:
The Cholangiocarcinoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
The total incident population of Cholangiocarcinoma in the US was estimated to be 5,567 cases in 2020
The United States showed the highest incident cases of Cholangiocarcinoma, as compared to EU5, and Japan. As per the estimates, the United States accounts for approximately 36.0% of total cases, for Cholangiocarcinoma, in the 7MM countries
In 2020, out of the total incident cases of Cholangiocarcinoma in around 3,724 cases were of Intrahepatic and 1,843 cases were of Extrahepatic Cholangiocarcinoma respectively.
Key Cholangiocarcinoma Companies: Delcath Systems, Basilea Pharmaceuticals, Zymeworks, BeiGene, Bayer, TaihoOncology, Merck, GlaxoSmithKline, Eisai, and others
Key Cholangiocarcinoma Therapies: Melphalan, Derazantinib, ZW25, Copanlisib (BAY 80-6946), E7090, Futibatinib (TAS-120), Bintrafusp alfa (GSK4045154; M7824), and others
The Cholangiocarcinoma epidemiology based on gender analyzed that in the 7MM, most of the patients with Cholangiocarcinoma were male
Get a Free sample for the Cholangiocarcinoma Market Report
Key benefits of the Cholangiocarcinoma Market report:
Cholangiocarcinoma market report covers a descriptive overview and comprehensive insight of the Cholangiocarcinoma Epidemiology and Cholangiocarcinoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Cholangiocarcinoma market report provides insights on the current and emerging therapies.
Cholangiocarcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Cholangiocarcinoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Cholangiocarcinoma market.
Discover more about therapies set to grab major Cholangiocarcinoma market share @ Cholangiocarcinoma market forecast
Cholangiocarcinoma Epidemiology Segmentation:
The Cholangiocarcinoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Cholangiocarcinoma
Prevalent Cases of Cholangiocarcinoma by severity
Gender-specific Prevalence of Cholangiocarcinoma
Diagnosed Cases of Episodic and Chronic Cholangiocarcinoma
Cholangiocarcinoma Market
The dynamics of the Cholangiocarcinoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Futibatinib (TAS-120), Bintrafusp alfa (GSK4045154; M7824), and others during the forecasted period 2019-2032.
Download the report to understand which factors are driving Cholangiocarcinoma epidemiology trends @ Cholangiocarcinoma Epidemiological Insights
Cholangiocarcinoma Market Drivers
Rising Cholangiocarcinoma Incidence
Technological advancements in the identification of biomarkers
Increasing Cholangiocarcinoma R&D Activities
Cholangiocarcinoma Therapies and Key Companies
Melphalan: Delcath Systems
Derazantinib: Basilea Pharmaceuticals
ZW25: Zymeworks/BeiGene
Copanlisib (BAY 80-6946): Bayer
E7090: Eisai
Futibatinib (TAS-120): TaihoOncology
Bintrafusp alfa (GSK4045154; M7824): Merck/GlaxoSmithKline
Scope of the Cholangiocarcinoma Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cholangiocarcinoma Companies: Delcath Systems, Basilea Pharmaceuticals, Zymeworks, BeiGene, Bayer, TaihoOncology, Merck, GlaxoSmithKline, Eisai, and others
Key Cholangiocarcinoma Therapies: Melphalan, Derazantinib, ZW25, Copanlisib (BAY 80-6946), E7090, Futibatinib (TAS-120), Bintrafusp alfa (GSK4045154; M7824), and others
Cholangiocarcinoma Therapeutic Assessment: Cholangiocarcinoma current marketed and Cholangiocarcinoma emerging therapies
Cholangiocarcinoma Market Dynamics: Cholangiocarcinoma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Cholangiocarcinoma Market Access and Reimbursement
Cholangiocarcinoma Market Barriers
Lack of awareness about the disease
Heterogeneity of the disease
Delayed Cholangiocarcinoma Diagnosis
Table of Contents
1. Cholangiocarcinoma Market Report Introduction
2. Executive Summary for Cholangiocarcinoma
3. SWOT analysis of Cholangiocarcinoma
4. Cholangiocarcinoma Patient Share (%) Overview at a Glance
5. Cholangiocarcinoma Market Overview at a Glance
6. Cholangiocarcinoma Disease Background and Overview
7. Cholangiocarcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Cholangiocarcinoma
9. Cholangiocarcinoma Current Treatment and Medical Practices
10. Cholangiocarcinoma Unmet Needs
11. Cholangiocarcinoma Emerging Therapies
12. Cholangiocarcinoma Market Outlook
13. Country-Wise Cholangiocarcinoma Market Analysis (2019–2032)
14. Cholangiocarcinoma Market Access and Reimbursement of Therapies
15. Cholangiocarcinoma Market drivers
16. Cholangiocarcinoma Market barriers
17. Cholangiocarcinoma Appendix
18. Cholangiocarcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Cholangiocarcinoma treatment, visit @ Cholangiocarcinoma Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
